The Next Chapter: BioNTech’s Bold Move Beyond COVID-19
BioNTech is shifting focus from COVID-19 vaccines to developing mRNA-based cancer therapies, aiming for market approval by 2026. The company reported a fourth-quarter earnings of €1.08 per share and revenue…